HUMA — Humacyte, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1818382 ·
Last close
$0.56
Market Cap
$154.73M
52W High
$2.55
52W Low
$0.53
ADV30
6,846,370
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 406,000 | -825,000 | -26,996,000 | -36,802,000 | 138,087,000 | 79,903,000 | 106,826,000 |
| Mar 2026 | 495,000 | -1,543,000 | -28,935,000 | -17,619,000 | 110,557,000 | 48,539,000 | 98,933,000 |
| Dec 2025 | 467,000 | -8,615,000 | -30,836,000 | -24,804,000 | 116,366,000 | 50,497,000 | 113,257,000 |
| Sep 2025 | 753,000 | 493,000 | -24,390,000 | -17,510,000 | 91,509,000 | 19,488,000 | 96,260,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-101,545,000
Investing CF
$-831,000
Financing CF
$38,068,000
CapEx
$-831,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.16
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-744,467,000
Inventory
$9,920,000
Receivables
$434,000
ST Investments
—
EBIT TTM
$-87,070,000
Pretax Income TTM
$-97,591,000
Interest Exp TTM
$10,521,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,121,000
EBITDA
$-103,228,000
Free Cash Flow
$-58,393,248
Enterprise Value
$144,655,200
Total Cash
$79,903,000
Total Debt
$66,880,000
Shares Out
277,798,105
Trailing EPS
$-0.52
Book Value
$0.11
ROE
-547.9%
ROA
-49.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,038,000 | -108,137,000 | -40,833,000 | 116,366,000 | 113,257,000 | 3,109,000 | -105,042,000 |
| Dec 2024 | 0 | -114,398,000 | -148,701,000 | 137,872,000 | 190,541,000 | -52,669,000 | -98,122,000 |
| Dec 2023 | 0 | -100,047,000 | -110,776,000 | 128,223,000 | 114,677,000 | 13,546,000 | -73,305,000 |
| Dec 2022 | 0 | -84,578,000 | -11,965,000 | 204,302,000 | 87,374,000 | 116,928,000 | -71,129,000 |
TTM Snapshot
Revenues TTM
$2,255,000
NetIncome TTM
$-122,041,000
OpCashFlow TTM
$0
Assets (Latest)
$137,872,000
Forward EPS
$-0.25
Max Pain — expiry 2027-01-15
max pain strike: $0.50 · spot: $0.54 · call oi: 9,013 · put oi: 1,184
Expected Move to 2027-01-15:
±$0.28
(50.93%) —
implied range
$0.27 –
$0.82
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | $155.81M | $0.64 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $161.99M | $2.24 | — |
| MOLN | MOLECULAR PARTNERS AG | $164.71M | $4.30 | — |
| VYGR | Voyager Therapeutics, Inc. | $165.14M | $2.68 | — |
| DTIL | PRECISION BIOSCIENCES INC | $171.68M | $6.22 | — |
News headlines (Yahoo Finance, 1h cache)
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
2026-09-28 12:00 · Yahoo
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
2026-09-18 22:00 · Yahoo
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
2026-09-17 13:30 · Yahoo
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:00 · Yahoo
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
2026-09-09 12:00 · Yahoo
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
2026-08-24 12:00 · Yahoo
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
2026-08-19 12:00 · Yahoo
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds
2026-08-13 21:09 · Yahoo
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall
2026-08-13 12:09 · Yahoo
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women
2026-08-13 11:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.